Elon Musk’s Neuralink has received approval to launch its first clinical trial in Canada, marking a significant step for the brain chip startup. The trial aims to assess the safety and functionality of its implant, designed to help paralyzed individuals use digital devices simply by thinking. The device, which targets those with quadriplegia (paralysis of all four limbs), allows users to control external devices using only their thoughts.
The trial will be conducted at the University Health Network hospital in Toronto, where the complex neurosurgical procedure will be performed. The hospital’s involvement highlights the high-level medical expertise required for such an advanced procedure.
Also Read: Barcelona plans to raise the cruise tourist tax
In the United States, Neuralink has already successfully implanted its device in two patients, with one of them reportedly using it to play video games and design 3D objects. Neuralink continues to make strides with its brain chip interface, which is being developed with the goal of helping disabled patients regain movement and communication abilities, as well as potentially restoring vision.
In September, Neuralink received a “breakthrough device” designation from the U.S. Food and Drug Administration (FDA) for its experimental implant aimed at restoring vision, highlighting the progress the company is making in medical device development.
